Advisors Asset Management Inc. bought a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 33,882 shares of the biotechnology company’s stock, valued at approximately $10,584,000. Advisors Asset Management Inc. owned 0.17% of Ligand Pharmaceuticals at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Ligand Pharmaceuticals in the 2nd quarter valued at approximately $1,359,000. Squarepoint Ops LLC raised its stake in Ligand Pharmaceuticals by 256.6% during the 2nd quarter. Squarepoint Ops LLC now owns 22,800 shares of the biotechnology company’s stock worth $7,207,000 after acquiring an additional 16,406 shares in the last quarter. JW Asset Management LLC purchased a new stake in Ligand Pharmaceuticals in the second quarter valued at $1,264,000. Hsbc Holdings PLC acquired a new stake in shares of Ligand Pharmaceuticals during the first quarter worth about $690,000. Finally, Bank of America Corp DE increased its position in shares of Ligand Pharmaceuticals by 31.4% during the first quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock worth $31,518,000 after purchasing an additional 37,696 shares in the last quarter. 91.28% of the stock is currently owned by hedge funds and other institutional investors.
Ligand Pharmaceuticals Stock Performance
Shares of LGND opened at $286.87 on Friday. Ligand Pharmaceuticals Incorporated has a 12-month low of $175.89 and a 12-month high of $326.63. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average of $302.35 and a two-hundred day moving average of $260.49. The stock has a market cap of $5.74 billion, a P/E ratio of 128.07, a PEG ratio of 5.01 and a beta of 1.16.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the stock. Royal Bank Of Canada raised their target price on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Weiss Ratings cut Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a research report on Monday, November 2nd. Leerink Partners initiated coverage on Ligand Pharmaceuticals in a research note on Friday, August 14th. They issued an “outperform” rating and a $330.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $358.00 target price on shares of Ligand Pharmaceuticals in a report on Thursday, September 24th. Finally, Citigroup boosted their target price on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $355.38.
Check Out Our Latest Research Report on Ligand Pharmaceuticals
Insider Activity
In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $313.22, for a total transaction of $1,566,100.00. Following the transaction, the insider owned 31,854 shares of the company’s stock, valued at $9,977,309.88. This represents a 13.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Kozarich sold 500 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $325.00, for a total value of $162,500.00. Following the completion of the transaction, the director owned 42,122 shares of the company’s stock, valued at $13,689,650. The trade was a 1.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 24,093 shares of company stock valued at $7,384,287 over the last quarter. Insiders own 5.60% of the company’s stock.
Ligand Pharmaceuticals Profile
Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report).
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
